Apotex Inc.

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 2 drugs with upcoming expirations

Activity

Recent Activity

Last 14 days

Jul 14, 2026

Completed

A Study Comparing the Bioequivalence of Triamcinolone Acetonide Aqueous Nasal Spray (Apotex, Inc.) to That of Nasacort® AQ Nasal Spray (Sanofi-Aventis Pharmaceutical Products, Inc.) In the Treatment of Seasonal Allergic Rhinitis

Earlier

May 1, 2026FDAYondelis — EVDI

Aug 18, 2023FDAAlkeran — IVRA

Aug 14, 2023FDAAlkeran — HEPZATO

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

7 patent groups across drugs · Source: FDA Orange Book

DrugExpires

Yondelis2 patentsJan 7, 2028 Alkeran3 patentsMay 28, 2030 Alkeran7 patentsNov 7, 2032 AlkeranJan 16, 2033 Alkeran3 patentsJan 30, 2034 AlkeranJun 29, 2036 YondelisFeb 18, 2043

Regulatory

Regulatory Timeline

19821 event

FDAJan 1

Alkeran — ALKERAN

Application NDA014691 (NDA)

19921 event

FDANov 18

Alkeran — ALKERAN

Application NDA020207 (NDA)

20151 event

FDAOct 23

Yondelis — YONDELIS

Application NDA207953 (NDA)

20161 event

FDAMar 10

Alkeran — EVOMELA

Application NDA207155 (NDA)

20232 events

FDAAug 18

Alkeran — IVRA

Application NDA217110 (NDA)

FDAAug 14

Alkeran — HEPZATO

Application NDA201848 (NDA)

20261 event

FDAMay 1

Yondelis — EVDI

Application NDA220837 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)